

October 31, 2024

## PRIOR AUTHORIZATION UPDATES FOR MARKETPLACE AND DSNP – EFFECTIVE JAN. 1, 2025

### SUMMARY OF NOTIFICATION

On January 1, 2025, preferred product criteria for the below are changing to fewer preferred products per drug. This will impact Marketplace and DSNP.

- Bevacizumab (procedure codes J9035, Q5107, Q5118, Q5126, Q5129)
- Infliximab (procedure codes J1745, Q5103, Q5104, Q5121)
- Pegfilgrastim (procedure codes J2506, Q5108, Q5130, Q5122, Q5127, Q5111)
- Rituximab (procedure codes J9312, Q5115, Q5119, Q5123)
- Trastuzumab (procedure codes J9355, Q5117, Q5114, Q5112, Q5113, Q5116)

### KEY DETAILS

- Bevacizumab preferred products will be Zirabev (Q5118) and Mvasi (Q5107)
- Infliximab preferred product will be Inflectra (Q5103)
- Pegfilgrastim preferred product will be Neulasta (J2506)
- Rituximab preferred product will be Ruxience (Q5119)
- Trastuzumab preferred products will be Trazimera (Q5116) and Kanjinti (Q5117)

Please refer to our [Prior Authorization Information Webpage](#) under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section for a complete, updated Medical Review Guidelines (MRGs).